Sector: Cannabis

Despite Canada's legalization of cannabis a year ago, a StatCan survey found that 42% of Canadians have obtained their cannabis from illegal sources.

On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.

The Hill reported yesterday that on November 20, the House Judiciary Committee plans to mark up legislation that federally decriminalizes marijuana.

Amid a subdued cannabis sector, Aurora Cannabis (ACB) stock has taken a serious hit and is down 36.4% this month. Is this the right time to invest?

On November 18, Aurora Cannabis (ACB) closed at 3 Canadian dollars on the TSX, a 16.43% drop and the third-worst trading day for it in three years.

So far, November has been tough for the cannabis sector. Most cannabis companies have reported lower-than-expected earnings.

In September, Minnesota's state legislators conducted surveys to determine public sentiment about cannabis legalization. About 55% favored legalization.

On November 15, MedMen (MMEN) (MMNFF) declared an extensive five-year restructuring plan in its attempt to become EBITDA-positive by 2020.

Last week, HEXO Corporation (HEXO) issued a press release that provided more information about its Niagara facility license.

Aurora Cannabis reported its third-quarter results after the market closed on November 14. Despite some positives, it fell 18% on November 15.